miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 12, 2025

Zacks Industry Outlook Highlights General Motors, Polaris and Blue Bird

View original at finance.yahoo.com
Zacks Industry Outlook Highlights General Motors, Polaris and Blue Bird For Immediate Release Chicago, IL – December 12, 2025 – Today, Zacks Equity Research discusses General Motors Co…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • More budget-friendly EVs are expected to expand adoption, while tariffs may limit foreign rivals, supporting domestic manufacturers

    80% confidence
  • Blue Bird expects fiscal 2026 revenues of $1.5 billion and adjusted EBITDA of $220 million

    80% confidence
  • In China, domestic EV companies have tightened their hold on the market, with their share jumping from 65% in the first half of 2020 to nearly 90% in the first half of 2025

    80% confidence
  • Someone paying $2,000 in annual interest on auto loan could save roughly $400 each year or about $2,000 across a five-year loan from the proposed tax deduction

    80% confidence
  • Blue Bird expects 2026 to mirror the record results delivered in 2025 and anticipates continued profitable growth in the years ahead as it works toward reaching approximately $2 billion in revenues and an adjusted EBITDA margin exceeding 16%

    80% confidence
  • Polaris expects adjusted sales in the range of $6.9 billion to $7.1 billion for 2025

    80% confidence
  • Chinese automakers boosted their collective share of Europe's total vehicle sales to around 5.1% in the first half of 2025, nearly double their share from a year earlier

    80% confidence
  • U.S. auto sales in 2025 will climb to 16.1-16.2 million units, up from 15.98 million in 2024

    80% confidence
  • The Zacks Domestic Auto industry is set for renewed momentum as affordable EVs and proposed tax incentives encourage buyers despite economic uncertainty and rising tariffs

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com